Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer

In cancer, mutations of DNA methylation modification genes have crucial roles for epigenetic modifications genome-wide, which lead to the activation or suppression of important genes including tumor suppressor genes. Mutations on the epigenetic modifiers could affect the enzyme activity, which would result in the difference in genome-wide methylation profiles and, activation of downstream genes. Therefore, we investigated the effect of mutations on DNA methylation modification genes such as DNMT1, DNMT3A, MBD1, MBD4, TET1, TET2 and TET3 through a pan-cancer analysis. First, we investigated the effect of mutations in DNA methylation modification genes on genome-wide methylation profiles. We collected 3,644 samples that have both of mRNA and methylation data from 12 major cancer types in The Cancer Genome Atlas (TCGA). The samples were divided into two groups according to the mutational signature. Differentially methylated regions (DMR) that overlapped with the promoter region were selected using minfi and differentially expressed genes (DEG) were identified using EBSeq. By integrating the DMR and DEG results, we constructed a comprehensive DNA methylome profiles on a pan-cancer scale. Second, we investigated the effect of DNA methylations in the promoter regions on downstream genes by comparing the two groups of samples in 11 cancer types. To investigate the effects of promoter methylation on downstream gene activations, we performed clustering analysis of DEGs. Among the DEGs, we selected highly correlated gene set that had differentially methylated promoter regions using graph based sub-network clustering methods. We chose an up-regulated DEGs cluster where had hypomethylated promoter in acute myeloid leukemia (LAML) and another down-regulated DEGs cluster where had hypermethylated promoter in colon adenocarcinoma (COAD). To rule out effects of gene regulation by transcription factor (TF), if differentially expressed TFs bound to the promoter of DEGs, that DEGs did not included to the gene set that effected by DNA methylation modifiers. Consequently, we identified 54 hypomethylated promoter DMR up-regulated DEGs in LAML and 45 hypermethylated promoter DMR down-regulated DEGs in COAD. Our study on DNA methylation modification genes in mutated vs. non-mutated groups could provide useful insight into the epigenetic regulation of DEGs in cancer.

[1]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[2]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[3]  Yun-Ching Chang,et al.  High incidence of acute promyelocytic leukemia specifically induced by N-nitroso-N-methylurea (NMU) in Sprague–Dawley rats , 2011, Archives of Toxicology.

[4]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[5]  D. Jesionek-Kupnicka,et al.  The Expression of the SLIT–ROBO Family in Adult Patients with Acute Myeloid Leukemia , 2019, Archivum Immunologiae et Therapiae Experimentalis.

[6]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[7]  G. Xue,et al.  DNA hypomethylation of CBS promoter induced by folate deficiency is a potential noninvasive circulating biomarker for colorectal adenocarcinomas. , 2017, Oncotarget.

[8]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[9]  Z. Li,et al.  Correlation between IL-7 genomic protein methylation level and acute myeloid leukemia. , 2019, European review for medical and pharmacological sciences.

[10]  S. Heim,et al.  Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia , 2011, Leukemia.

[11]  A. Kohlmann,et al.  The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL , 2013, Genes, chromosomes & cancer.

[12]  Wancai Yang,et al.  Tumor suppressor PRSS8 targets Sphk1/S1P/Stat3/Akt signaling in colorectal cancer , 2016, Oncotarget.

[13]  Li-hui Wang,et al.  Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions , 2006, Modern Pathology.

[14]  R. Chai,et al.  Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest through the caspase-3 and PARP pathways. , 2015, International journal of molecular medicine.

[15]  T. Möröy,et al.  Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia , 2009, International journal of hematology.

[16]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[17]  T. Down,et al.  Genome Wide Analysis of Acute Myeloid Leukemia Reveal Leukemia Specific Methylome and Subtype Specific Hypomethylation of Repeats , 2012, PloS one.

[18]  Andrew P. Feinberg,et al.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression , 2016, Nature Reviews Genetics.

[19]  K. Mitani,et al.  Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13). , 2005, Cancer research.

[20]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[21]  Ning Leng,et al.  EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments , 2013, Bioinform..

[22]  O. Bernard,et al.  TET proteins and the control of cytosine demethylation in cancer , 2015, Genome Medicine.

[23]  Huayao Li,et al.  Developing DNA methylation‐based prognostic biomarkers of acute myeloid leukemia , 2018, Journal of cellular biochemistry.

[24]  J. Mariadason HDACs and HDAC inhibitors in colon cancer , 2008, Epigenetics.

[25]  Christian Bastard,et al.  TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.

[26]  T. Ushijima,et al.  Silencing of the UCHL1 gene in human colorectal and ovarian cancers , 2006, International journal of cancer.

[27]  David A. Williams,et al.  Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. , 2014, Cell stem cell.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[29]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[30]  L. Milani,et al.  DNA Methylation Analysis of Bone Marrow Cells at Diagnosis of Acute Lymphoblastic Leukemia and at Remission , 2012, PloS one.

[31]  Pavel Burda,et al.  GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia , 2016, PloS one.

[32]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[33]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[34]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[35]  S. Bohlander,et al.  Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. , 2013, Blood.

[36]  Min Zhao,et al.  The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers. , 2019, Gene.

[37]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[38]  Dawei Li,et al.  RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis , 2015, Oncotarget.

[39]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[40]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[41]  R. Solana,et al.  Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients , 2012, Immunology and cell biology.

[42]  Hyeongmin Kim,et al.  Pan-cancer analysis of somatic mutations and transcriptomes reveals common functional gene clusters shared by multiple cancer types , 2018, Scientific Reports.

[43]  Lisa L. Smith,et al.  Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets , 2004, Cancer Research.

[44]  K. Mimori,et al.  Clinical significance of ASB9 in human colorectal cancer. , 2010, International journal of oncology.

[45]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.